This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Dose-Related Thrombocytopenia and Macrocytic Anemia Associated With Valproate Use in Bipolar Disorder

Robert G. Fawcett

Published: March 15, 1997

Article Abstract

Letter to the Editor

Sir: A recent report on hematologic effects of anticonvulsants
used for treating psychiatric inpatients showed a total absence
of drug-related thrombocytopenia and anemia in 1251
patients treated with valproate. In contradistinction, various
authors report low platelet counts in adults and children treated
for seizures and other neurologic disorders with valproate.
One study found a mean reduction in platelet count of
49,000/µL below baseline at doses near 1500 mg/day of valproate
and of 69,000/µL at doses near 2800 mg/day. Since
thrombocytopenia has not been reported in a psychiatric population
treated with valproate, I report a case of a patient with
bipolar I disorder who developed thrombocytopenia and anemia
associated with valproate treatment.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 58

Quick Links: Bipolar Disorder

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...